Structure and Governance

Chair

Since 2006, Jean-François Leprince has been a Managing Partner at CTI Life Sciences Fund, a private venture capital company funding Canadian and U.S. biotechnology companies.

After obtaining a chemical engineering degree from the Institut national supérieur de chimie industrielle, in Rouen (France), he started his working career at Dow Chemical Company in the Specialty Chemicals Division before joining the Pharmaceutical Division in 1978. In various management and operational roles, Mr Leprince has travelled extensively to Belgium, Switzerland, France and to the Middle-East, Africa and South-East Asia. With the sale of Marion Merrell Dow to Hoechst in 1995, Mr Leprince became the Managing Director of one of Hoechst Marion Roussel’s three subsidiaries in France. In 1998, Mr Leprince became President of Hoechst Marion Roussel Canada and then of Aventis Canada as a result of the merger between Hoechst Marion Roussel and Rhone Poulenc Rorer, a role he held until the end of 2004.

While President of Aventis Canada, he served on the Board of Directors of former Rx&D (Canada’s Research-Based Pharmaceutical Companies), now named Innovative Medicines Canada, and was appointed Chair in 2002.

Mr Leprince served as President & CEO of GLyPharma Therapeutic Inc., a Montreal-based CTI Life Sciences Fund portfolio company until its acquisition by Swiss-based Therachon AG in September 2018.

He serves as Director of ILKOS THERAPEUTIC INC., another CTI Life Sciences Fund portfolio company resulting from a partnership with Laboratoires Servier-France.

Mr Leprince also serves on the Board of AllerGen and most recently was elected as Chairman of the Board of IRICoR. Both organizations are funded by the Networks of Centres of Excellence of Canada (NCE).

Jean-François Leprince, B.ENG.Managing Partner, CTI Life Sciences Fund

Since 2006, Jean-François Leprince has been a Managing Partner at CTI Life Sciences Fund, a private venture capital company funding Canadian and U.S. biotechnology companies.

After obtaining a chemical engineering degree from the Institut national supérieur de chimie industrielle, in Rouen (France), he started his working career at Dow Chemical Company in the Specialty Chemicals Division before joining the Pharmaceutical Division in 1978. In various management and operational roles, Mr Leprince has travelled extensively to Belgium, Switzerland, France and to the Middle-East, Africa and South-East Asia. With the sale of Marion Merrell Dow to Hoechst in 1995, Mr Leprince became the Managing Director of one of Hoechst Marion Roussel’s three subsidiaries in France. In 1998, Mr Leprince became President of Hoechst Marion Roussel Canada and then of Aventis Canada as a result of the merger between Hoechst Marion Roussel and Rhone Poulenc Rorer, a role he held until the end of 2004.

While President of Aventis Canada, he served on the Board of Directors of former Rx&D (Canada’s Research-Based Pharmaceutical Companies), now named Innovative Medicines Canada, and was appointed Chair in 2002.

Mr Leprince served as President & CEO of GLyPharma Therapeutic Inc., a Montreal-based CTI Life Sciences Fund portfolio company until its acquisition by Swiss-based Therachon AG in September 2018.

He serves as Director of ILKOS THERAPEUTIC INC., another CTI Life Sciences Fund portfolio company resulting from a partnership with Laboratoires Servier-France.

Mr Leprince also serves on the Board of AllerGen and most recently was elected as Chairman of the Board of IRICoR. Both organizations are funded by the Networks of Centres of Excellence of Canada (NCE).

 

Members

Frédéric Alberro began his career in 1995 in the government of Quebec as International Affairs Advisor to the Ministry of Industry, Trade, Science and Technology of Quebec (MICST) and special advisor to the Coordination of major economic projects Center of the Executive Council of Quebec.

Enthusiast economic development of Quebec, he later served as economic advisor to the Premier of Quebec from 1998 to 2001, Director of Economic Affairs of the Québec Government Office in Boston from 2001 to 2003 and again economic adviser of Premier of Quebec in 2003 and of the leader of the official opposition from 2003 to 2005.Mr. Alberro then acts as spokesperson for the AMF from 2005 to 2007.After over 12 years in the public system, Mr. Alberro worked in economic associations respectively occupy the function of Vice President Québec of the Canadian Council of Grocery Distributors and Vice President Québec the Retail Canadian Council. Through that, he has served on several Board of Directors, including Québec Food Banks.

Since 2011, he is the Director Québec of the Innovative Medicines Canada (former Rx&D)

Mr. Alberro has a BA in Business Administration from the Business School of UQQM and holds a Master of International Affairs from École Supérieure de Commerce de Sophia-Antipolis (Nice, France).

Frederic_Alberro
Frédéric AlberroDirector Québec, Innovative Medicines Canada

Frédéric Alberro began his career in 1995 in the government of Quebec as International Affairs Advisor to the Ministry of Industry, Trade, Science and Technology of Quebec (MICST) and special advisor to the Coordination of major economic projects Center of the Executive Council of Quebec.

Enthusiast economic development of Quebec, he later served as economic advisor to the Premier of Quebec from 1998 to 2001, Director of Economic Affairs of the Québec Government Office in Boston from 2001 to 2003 and again economic adviser of Premier of Quebec in 2003 and of the leader of the official opposition from 2003 to 2005.Mr. Alberro then acts as spokesperson for the AMF from 2005 to 2007.After over 12 years in the public system, Mr. Alberro worked in economic associations respectively occupy the function of Vice President Québec of the Canadian Council of Grocery Distributors and Vice President Québec the Retail Canadian Council. Through that, he has served on several Board of Directors, including Québec Food Banks.

Since 2011, he is the Director Québec of the Innovative Medicines Canada (former Rx&D)

Mr. Alberro has a BA in Business Administration from the Business School of UQQM and holds a Master of International Affairs from École Supérieure de Commerce de Sophia-Antipolis (Nice, France).

Since 2016, Dr. Nadine Beauger is Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR). Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) activities. She led strategic IP portfolio management including a dedicated IP budget, building and implementing the strategy for portfolio of patent families (40) which have led to successful licensing agreements and partnerships with industry (multi-million$ in total deal value).

Nadine began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm. Just prior to joining IRICoR, Dr. Beauger was Manager of the Business Development at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Association of University Transfer Managers (AUTM).

0001_NBeauger
Nadine Beauger, Ph.D., MBAPresident, Chief Executive Officer

Since 2016, Dr. Nadine Beauger is Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR). Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) activities. She led strategic IP portfolio management including a dedicated IP budget, building and implementing the strategy for portfolio of patent families (40) which have led to successful licensing agreements and partnerships with industry (multi-million$ in total deal value).

Nadine began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm. Just prior to joining IRICoR, Dr. Beauger was Manager of the Business Development at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Association of University Transfer Managers (AUTM).

Mr. Bernier is co-founder and Managing Partner at Teralys Capital. He is a highly respected venture capitalist, entrepreneur and investor who has helped shape the Canadian technological innovation scene. Through a 35-year career of contributions to the high-tech community, he has been actively involved in more than a dozen emerging high-tech companies as founder or angel investor as well as Senior Vice-President of the Fonds de solidarité FTQ. Mr. Bernier’s widely valued wisdom and experience continue to define, develop and implement a new approach to venture capital in Canada and abroad. He serves on the board of PolyFinances, InnoCité Montréal, Quartier de l’Innovation, IRIC and he also does philanthropy work.

Mr. Bernier holds a Bachelor’s degree in Industrial Engineering from École polytechnique de Montréal (B.A.Sc.)

Jacques_Bernier
Jacques Bernier, B.ENGCo-founder and Managing Partner, Teralys Capital

Mr. Bernier is co-founder and Managing Partner at Teralys Capital. He is a highly respected venture capitalist, entrepreneur and investor who has helped shape the Canadian technological innovation scene. Through a 35-year career of contributions to the high-tech community, he has been actively involved in more than a dozen emerging high-tech companies as founder or angel investor as well as Senior Vice-President of the Fonds de solidarité FTQ. Mr. Bernier’s widely valued wisdom and experience continue to define, develop and implement a new approach to venture capital in Canada and abroad. He serves on the board of PolyFinances, InnoCité Montréal, Quartier de l’Innovation, IRIC and he also does philanthropy work.

Mr. Bernier holds a Bachelor’s degree in Industrial Engineering from École polytechnique de Montréal (B.A.Sc.)

Catherine Bouchard has more than ten years of experience in healthcare equity research. She joined la Caisse de dépôt et placement du Québec in March 2012 as senior healthcare analyst. With her team, she is responsible of developing fundamental and investable perspectives on the global healthcare sector and to orient decision-makers accordingly, including portfolio managers, private equity teams, investment committees and supervisory boards. She uses her broad knowledge to assess and recommend stocks, bonds or specialized assets (royalties, real estate). Prior to joining CDPQ, Ms. Bouchard spent five years at Valeurs Mobilières Banque Laurentienne, where she was the lead analyst covering healthcare stocks. She holds a MBA and a M.Sc. in Biomedical Sciences.

Catherine Bouchard, MSc, MBADirector Healthcare Research, Caisse de dépôt et placement du Québec

Catherine Bouchard has more than ten years of experience in healthcare equity research. She joined la Caisse de dépôt et placement du Québec in March 2012 as senior healthcare analyst. With her team, she is responsible of developing fundamental and investable perspectives on the global healthcare sector and to orient decision-makers accordingly, including portfolio managers, private equity teams, investment committees and supervisory boards. She uses her broad knowledge to assess and recommend stocks, bonds or specialized assets (royalties, real estate). Prior to joining CDPQ, Ms. Bouchard spent five years at Valeurs Mobilières Banque Laurentienne, where she was the lead analyst covering healthcare stocks. She holds a MBA and a M.Sc. in Biomedical Sciences.

 

Michel Bouvier holds a B.Sc. in biochemistry (1979) and a Ph.D in Neurological Sciences (1985) from the Université de Montréal and obtained post-doctoral training (1985-89) at Duke University under the supervision of Dr. R.J. Lefkowitz (Nobel prize Chemistry 2012). He is professor of Biochemistry and Molecular Medicine at the Faculty of Medicine of the Université de Montréal and principal investigator and at the Institute for Research in Immunology and Cancer. Dr. Bouvier is a world-renowned expert in the field of cell signalling and G protein-coupled receptors (GPCR) and made seminal contributions to our understanding of this major class of drug targets. His work on GPCR regulation led to paradigm shifts (inverse agonism, pharmacological chaperones, GPCR oligomerization, pluridimensionality of signalling), which coupled to his pioneering of bioluminescence resonance energy transfer (BRET) approaches, have direct impacts on drug discovery.

He is the author of over 260 scientific papers which received over 24,000 citations and delivered more than 400 invited conferences. He also holds 10 patents. His publications received more than 18,000 citations, leading to a Hirsh (h) index of 74 and his introduction on the 2014 Thomson Reuters’ list of the most cited scientists. His work was recognized by many awards, including his induction to the Academy of Sciences of the Royal Society of Canada in 2014. He trained 48 graduate students and 36 post-doctoral fellows, many of whom now hold professor and researcher positions around the world.

He currently holds the Canada research Chair in Signal Transduction and Molecular Pharmacology and is the general director of the Institute of Research in Immunology and Cancer.

Michel Bouvier is the Chief Executive Officer of IRIC, Deputy Vice-Rector Research, Discovery,Creation and Innovation at UdeM, and co-funder of IRICoR.

Michel_Bouvier
Michel Bouvier, Ph.D., FCAHS, FRSCCEO, Institute of Research in Immunology and Cancer

Michel Bouvier holds a B.Sc. in biochemistry (1979) and a Ph.D in Neurological Sciences (1985) from the Université de Montréal and obtained post-doctoral training (1985-89) at Duke University under the supervision of Dr. R.J. Lefkowitz (Nobel prize Chemistry 2012). He is professor of Biochemistry and Molecular Medicine at the Faculty of Medicine of the Université de Montréal and principal investigator and at the Institute for Research in Immunology and Cancer. Dr. Bouvier is a world-renowned expert in the field of cell signalling and G protein-coupled receptors (GPCR) and made seminal contributions to our understanding of this major class of drug targets. His work on GPCR regulation led to paradigm shifts (inverse agonism, pharmacological chaperones, GPCR oligomerization, pluridimensionality of signalling), which coupled to his pioneering of bioluminescence resonance energy transfer (BRET) approaches, have direct impacts on drug discovery.

He is the author of over 260 scientific papers which received over 24,000 citations and delivered more than 400 invited conferences. He also holds 10 patents. His publications received more than 18,000 citations, leading to a Hirsh (h) index of 74 and his introduction on the 2014 Thomson Reuters’ list of the most cited scientists. His work was recognized by many awards, including his induction to the Academy of Sciences of the Royal Society of Canada in 2014. He trained 48 graduate students and 36 post-doctoral fellows, many of whom now hold professor and researcher positions around the world.

He currently holds the Canada research Chair in Signal Transduction and Molecular Pharmacology and is the general director of the Institute of Research in Immunology and Cancer.

Michel Bouvier is the Chief Executive Officer of IRIC, Deputy Vice-Rector Research, Discovery,Creation and Innovation at UdeM, and co-funder of IRICoR.

In his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association. In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada.

Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. In those roles he held responsibility for the Association’s government relations, communications, media relations, advertising and international trade undertakings. From 1993-2004 he held the position of Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew held political assistant positions with a Member of Parliament and the Minister of State (Finance).

Andrew Casey is a native of Montreal, Quebec. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a Bachelor of Arts degree in Political Science.

Andre_Casey
Andrew CaseyPresident and CEO, BIOTECanada

In his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association. In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada.

Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. In those roles he held responsibility for the Association’s government relations, communications, media relations, advertising and international trade undertakings. From 1993-2004 he held the position of Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew held political assistant positions with a Member of Parliament and the Minister of State (Finance).

Andrew Casey is a native of Montreal, Quebec. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a Bachelor of Arts degree in Political Science.

Mtre. Annie Gauthier is a lawyer and a partner at the law firm BCF and specializes in business law, mergers and acquisitions, and corporate law. With over 15 years’ experience, she is one of the most respected lawyers in the field of technology and life sciences, and more specifically in the pharmaceutical industry.

Before joining BCF, Annie has practised with a nationally and internationally renowned law firm and worked on highly complex major transactions in addition to becoming one of the leading licensing experts in Canada.

Annie was also Director, Transactions at Pharmascience, the largest employer in the pharmaceutical industry in Quebec. This experience gave her inside understanding of the industry and an opportunity to conduct transactions on every continent.

Annie is actively involved with her peers and her community, and was also the President of the Montreal chapter of the Licensing Executives Society for over five years before becoming a member of the board of directors for the North American region of the organization in 2016. In 2014, she co-founded L’étoffe du succès Montréal, an organization dedicated to helping women that is affiliated with Dress for Success Worldwide.

Mtre. Gauthier graduated cum laude from McGill University with a Bachelor of Civil Law (B.C.L.) and a Bachelor of Laws (LL.B.) degrees from McGill University. She is member of the Quebec Bar since 2002.

Annie GauthierPartner and Lawyer, BCF

Mtre. Annie Gauthier is a lawyer and a partner at the law firm BCF and specializes in business law, mergers and acquisitions, and corporate law. With over 15 years’ experience, she is one of the most respected lawyers in the field of technology and life sciences, and more specifically in the pharmaceutical industry.

Before joining BCF, Annie has practised with a nationally and internationally renowned law firm and worked on highly complex major transactions in addition to becoming one of the leading licensing experts in Canada.

Annie was also Director, Transactions at Pharmascience, the largest employer in the pharmaceutical industry in Quebec. This experience gave her inside understanding of the industry and an opportunity to conduct transactions on every continent.

Annie is actively involved with her peers and her community, and was also the President of the Montreal chapter of the Licensing Executives Society for over five years before becoming a member of the board of directors for the North American region of the organization in 2016. In 2014, she co-founded L’étoffe du succès Montréal, an organization dedicated to helping women that is affiliated with Dress for Success Worldwide.

Mtre. Gauthier graduated cum laude from McGill University with a Bachelor of Civil Law (B.C.L.) and a Bachelor of Laws (LL.B.) degrees from McGill University. She is member of the Quebec Bar since 2002.

Bettina Hamelin is the President and CEO of Ontario Genomics.  Before assuming her current role in August 2017, Bettina served as Vice-President of NSERC’s Research Partnerships Directorate, where she was responsible for a range of programs designed to stimulate increased public/private sector collaboration and technology transfer by connecting the Canadian research enterprise to Canadian and global innovation stakeholders. Bettina has more than 15 years of experience in the biotech and international pharmaceutical industry as well as 10 years of academic experience as a tenured professor at the Faculty of Pharmacy at Université Laval.

Prior to joining NSERC Bettina held a variety of leadership positions at Pfizer Canada, most recently as Canadian Medical Lead, Vaccines, and Head, Strategic Research Partnerships, Western Canada. Passionate about R&D, she excels at bringing together unlikely partners to attract and leverage funds from diverse sources. She is known for pioneering novel public-private partnership models, and breaking down barriers between federal, provincial and private sector stakeholders.

Early roots in biology and chemistry (Vordiplom, Universität Kaiserslautern, Germany) have led Bettina to complete a B.Sc. in pharmacy and a Doctor of Pharmacy, both from the University of Kentucky, U.S. and an EMBA in Healthcare from the University of British Columbia, Canada.

Bettina Hamelin, OharmD, EMBAPresident and CEO, Ontario Genomics

Bettina Hamelin is the President and CEO of Ontario Genomics.  Before assuming her current role in August 2017, Bettina served as Vice-President of NSERC’s Research Partnerships Directorate, where she was responsible for a range of programs designed to stimulate increased public/private sector collaboration and technology transfer by connecting the Canadian research enterprise to Canadian and global innovation stakeholders. Bettina has more than 15 years of experience in the biotech and international pharmaceutical industry as well as 10 years of academic experience as a tenured professor at the Faculty of Pharmacy at Université Laval.

Prior to joining NSERC Bettina held a variety of leadership positions at Pfizer Canada, most recently as Canadian Medical Lead, Vaccines, and Head, Strategic Research Partnerships, Western Canada. Passionate about R&D, she excels at bringing together unlikely partners to attract and leverage funds from diverse sources. She is known for pioneering novel public-private partnership models, and breaking down barriers between federal, provincial and private sector stakeholders.

Early roots in biology and chemistry (Vordiplom, Universität Kaiserslautern, Germany) have led Bettina to complete a B.Sc. in pharmacy and a Doctor of Pharmacy, both from the University of Kentucky, U.S. and an EMBA in Healthcare from the University of British Columbia, Canada.

Dr. Marie-Josée Hébert is Professor of Medicine at the Faculty of Medicine at Université de Montréal, researcher at the CHUM research centre and nephrologist–transplant physician at CHUM. She holds the Shire Chair in Renal Transplantation and Regeneration at the Université de Montréal. Dr Hébert is the co-director of the Canadian National Transplant Research Program (CNTRP). Dr. Hébert’s laboratory focuses on the role of programmed cell death as a major pathway contributing to immune dysregulation, rejection and abnormal vascular repair. Her work builds on cellular and molecular biology approaches in association with animal models of rejection and proteomics strategies and validation in patients samples to characterize novel biomarkers and effectors of rejection and vascular remodeling. Findings from her team have led to the characterization of new mediators of rejection and renal failure in humans. They also contribute to a better understanding of the mechanisms of fibrogenesis triggered by endothelial injury, autophagy and apoptosis. Her work is supported by the Canadian Institutes of Health Research, Fonds de la recherche du Québec – Santé, Canadian Foundation for Innovation, Kidney Foundation of Canada and Fondation Jean-Louis Lévesque.

Dr. Hébert has been appointed Vice-rector – Research, Discovery, Creation and Innovation at Université de Montréal in November 2015. As such, she assumes the coordination of all UdeM research activities at the local, national and international levels. Her mandate also includes creation activities which involves many faculties at UdeM and extends to commercialization and valorization.

Mme_Hebert
Marie-Josée Hébert, Ph.D.Vice-Rector Research, Discovery, Creation and Innovation, Université de Montréal

Dr. Marie-Josée Hébert is Professor of Medicine at the Faculty of Medicine at Université de Montréal, researcher at the CHUM research centre and nephrologist–transplant physician at CHUM. She holds the Shire Chair in Renal Transplantation and Regeneration at the Université de Montréal. Dr Hébert is the co-director of the Canadian National Transplant Research Program (CNTRP). Dr. Hébert’s laboratory focuses on the role of programmed cell death as a major pathway contributing to immune dysregulation, rejection and abnormal vascular repair. Her work builds on cellular and molecular biology approaches in association with animal models of rejection and proteomics strategies and validation in patients samples to characterize novel biomarkers and effectors of rejection and vascular remodeling. Findings from her team have led to the characterization of new mediators of rejection and renal failure in humans. They also contribute to a better understanding of the mechanisms of fibrogenesis triggered by endothelial injury, autophagy and apoptosis. Her work is supported by the Canadian Institutes of Health Research, Fonds de la recherche du Québec – Santé, Canadian Foundation for Innovation, Kidney Foundation of Canada and Fondation Jean-Louis Lévesque.

Dr. Hébert has been appointed Vice-rector – Research, Discovery, Creation and Innovation at Université de Montréal in November 2015. As such, she assumes the coordination of all UdeM research activities at the local, national and international levels. Her mandate also includes creation activities which involves many faculties at UdeM and extends to commercialization and valorization.

Bernard Lachapelle is the President of The JBL Group Inc., one of Canada’s leading pharmaceutical pricing and reimbursement consultancies, which he founded in 2000.

A recognized expert in Health Policy and Market Access as well as a passionate advocate, Bernard’s counsel is sought by industry leaders and policy makers across Canada and abroad, and he is frequently called as a speaker and as a moderator. Over the years, Bernard and his team have greatly contributed to Canadian patients’ access to medicines by solving some of the most challenging and complex pricing and reimbursement issues.

Prior to JBL, Bernard held senior executive positions with global pharmaceutical companies in Canada, acquiring extensive experience in government affairs, market access, health policy development and corporate communications as well as marketing, pricing and tendering, and human resources. Bernard also held global responsibilities in intellectual property and international trade.
A graduate in Pharmacy and Biochemistry from Laval University, Bernard has long been involved in the political process and continues to serve the community in several capacities. Bernard is a member of the Board of the Fondation québécoise du cancer and Chairman of the prestigious Prix Galien in Canada.

Bernard LachapellePresident, JBL Group Inc.

Bernard Lachapelle is the President of The JBL Group Inc., one of Canada’s leading pharmaceutical pricing and reimbursement consultancies, which he founded in 2000.

A recognized expert in Health Policy and Market Access as well as a passionate advocate, Bernard’s counsel is sought by industry leaders and policy makers across Canada and abroad, and he is frequently called as a speaker and as a moderator. Over the years, Bernard and his team have greatly contributed to Canadian patients’ access to medicines by solving some of the most challenging and complex pricing and reimbursement issues.

Prior to JBL, Bernard held senior executive positions with global pharmaceutical companies in Canada, acquiring extensive experience in government affairs, market access, health policy development and corporate communications as well as marketing, pricing and tendering, and human resources. Bernard also held global responsibilities in intellectual property and international trade.
A graduate in Pharmacy and Biochemistry from Laval University, Bernard has long been involved in the political process and continues to serve the community in several capacities. Bernard is a member of the Board of the Fondation québécoise du cancer and Chairman of the prestigious Prix Galien in Canada.

Since 2016, Dr. Nadine Beauger is Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR). Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) activities. She led strategic IP portfolio management including a dedicated IP budget, building and implementing the strategy for portfolio of patent families (40) which have led to successful licensing agreements and partnerships with industry (multi-million$ in total deal value).

Nadine began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm. Just prior to joining IRICoR, Dr. Beauger was Manager of the Business Development at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Association of University Transfer Managers (AUTM).

0001_NBeauger
Nadine Beauger, Ph.D., MBAPresident, Chief Executive Officer

Since 2016, Dr. Nadine Beauger is Chief Executive Officer at the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR). Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property, academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related intellectual property (IP) activities. She led strategic IP portfolio management including a dedicated IP budget, building and implementing the strategy for portfolio of patent families (40) which have led to successful licensing agreements and partnerships with industry (multi-million$ in total deal value).

Nadine began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management of biotechnology patent applications. She went on as Associate at VantagePoint Venture Partners, a leading California headquartered venture capital firm. Just prior to joining IRICoR, Dr. Beauger was Manager of the Business Development at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal.

She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), a M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger is a member of the Association of University Transfer Managers (AUTM).

Dre Violetta Dimitriadou joined IRICoR in 2019. She began her professional career in academic education and basic research and held the position of Senior Lecturer in Pharmacy at René Descartes University (Paris, France). She is associated with over 100 scientific publications and presentations.

Over the last 25 years, Ms. Dimitriadou has specialized in drug development at various Canadian biotechnology companies, where she was responsible for research and development programs and the preclinical and clinical development of new chemical entities. More recently, as Vice President of Drug Development at GLyPharma Therapeutics, she was in charge of the apraglutide development program that was awarded the “orphan drug” designation by the EMA and FDA and is currently in the advanced clinical phase.

She also has extensive expertise in setting up and monitoring collaborations with research institutes and pharmaceutical companies, and has overseen large groups of scientists and technicians.

Dre Dimitriadou’s responsibilities will include developing the operational plan and the strategic objectives to support R&D initiatives, planning and implementing a balanced portfolio strategy, assessing the scientific and commercial potential of drug discovery projects and making investment recommendations.

Violetta holds a Ph.D. in Neurosciences/Cytology from l’Université Pierre et Marie Curie (Paris, France) and completed a two-year fellowship at Tufts University (Boston, MA) in the Neuropharmacology Department.

Violetta Dimitriadou, Ph.D.Vice-President, Scientific Operations

Dre Violetta Dimitriadou joined IRICoR in 2019. She began her professional career in academic education and basic research and held the position of Senior Lecturer in Pharmacy at René Descartes University (Paris, France). She is associated with over 100 scientific publications and presentations.

Over the last 25 years, Ms. Dimitriadou has specialized in drug development at various Canadian biotechnology companies, where she was responsible for research and development programs and the preclinical and clinical development of new chemical entities. More recently, as Vice President of Drug Development at GLyPharma Therapeutics, she was in charge of the apraglutide development program that was awarded the “orphan drug” designation by the EMA and FDA and is currently in the advanced clinical phase.

She also has extensive expertise in setting up and monitoring collaborations with research institutes and pharmaceutical companies, and has overseen large groups of scientists and technicians.

Dre Dimitriadou’s responsibilities will include developing the operational plan and the strategic objectives to support R&D initiatives, planning and implementing a balanced portfolio strategy, assessing the scientific and commercial potential of drug discovery projects and making investment recommendations.

Violetta holds a Ph.D. in Neurosciences/Cytology from l’Université Pierre et Marie Curie (Paris, France) and completed a two-year fellowship at Tufts University (Boston, MA) in the Neuropharmacology Department.

Dr. Steven Klein is IRICoR’s VP, Business Development. With over 15 years of experience in a variety of fields, including oncology, vaccines, and CNS-related indications, Dr Klein bring an invaluable knowledge of the private sector and of private-public initiatives.

At IRICoR since 2011, he has successfully negotiated and managed agreements with a variety of private sector partners, including BMS, Merck, Pfizer, AstraZeneca, Domain Therapeutics, Encycle Therapeutics, Cyclenium Pharmaceuticals, and AmorChem, as well as IRICoR’s alliances with its CECR and academic partners, including MaRS Innovation, CCRM, Neomed, CDRD, and the Hospital for Sick Children.  Dr. Klein also represented IRICoR in creating its recent spin-off companies ExCellThera and SpecificiT.

Prior to joining IRICoR, Dr. Klein held Business Development roles at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) where he negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Roche, GSK, Grunenthal, Sanofi Pasteur, Becton Dickinson, and Nippon Shinyaku.

Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.

Dr. Klein is a Board member of the Centre for the Commercialization of Antibodies and Biologics (CCAB), and has recently been asked to serve as a reviewer for the CIHR’s Commercialization committee in the upcoming Project Grant competition.

0002_SKlein
Steven J. Klein, Ph.D., MBAVice-President, Business Development

Dr. Steven Klein is IRICoR’s VP, Business Development. With over 15 years of experience in a variety of fields, including oncology, vaccines, and CNS-related indications, Dr Klein bring an invaluable knowledge of the private sector and of private-public initiatives.

At IRICoR since 2011, he has successfully negotiated and managed agreements with a variety of private sector partners, including BMS, Merck, Pfizer, AstraZeneca, Domain Therapeutics, Encycle Therapeutics, Cyclenium Pharmaceuticals, and AmorChem, as well as IRICoR’s alliances with its CECR and academic partners, including MaRS Innovation, CCRM, Neomed, CDRD, and the Hospital for Sick Children.  Dr. Klein also represented IRICoR in creating its recent spin-off companies ExCellThera and SpecificiT.

Prior to joining IRICoR, Dr. Klein held Business Development roles at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) where he negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Roche, GSK, Grunenthal, Sanofi Pasteur, Becton Dickinson, and Nippon Shinyaku.

Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.

Dr. Klein is a Board member of the Centre for the Commercialization of Antibodies and Biologics (CCAB), and has recently been asked to serve as a reviewer for the CIHR’s Commercialization committee in the upcoming Project Grant competition.

Since joining IRICoR in 2009 as Project Manager, Alix Molinier has been responsible of the financial and administrative tasks, monitoring IRICoR’s portfolio projects. She also actively contributes to the development of follow-up and analysis tools for internal uses, and to the gathering of competitive intelligence around portfolio projects.

Ms. Molinier has over 12 years of experience in project management, with a specific focus on biotechnology start-up companies both from a scientific and a human resource standpoint. Alix began her career as an Analyst and Project Officer at Grand Luminy Incubator, a Marseille-based strategic support and logistics facility that assists in the creation of biotechnology businesses, where she undertook competitive intelligence analysis for the organization’s clients. She continued performing competitive intelligence analysis as an Analyst at CEIM (Centre d’entreprises et d’innovation de Montréal), an incubator of new technology companies. Just prior to joining IRICoR, she was Project Officer at Pharmabio Development, a Work Force sectoral Committee for pharmaceutical and biotechnology companies.

Ms. Molinier led her Engineering and Master II curricula in parallel. She holds a double Diploma in Project Management specializing in Biotechnology from Euromed Marseille – Management School and from ESIL (École Supérieure d’Ingénieurs de Luminy).

0004_AMolinier
Alix MolinierProject Manager

Since joining IRICoR in 2009 as Project Manager, Alix Molinier has been responsible of the financial and administrative tasks, monitoring IRICoR’s portfolio projects. She also actively contributes to the development of follow-up and analysis tools for internal uses, and to the gathering of competitive intelligence around portfolio projects.

Ms. Molinier has over 12 years of experience in project management, with a specific focus on biotechnology start-up companies both from a scientific and a human resource standpoint. Alix began her career as an Analyst and Project Officer at Grand Luminy Incubator, a Marseille-based strategic support and logistics facility that assists in the creation of biotechnology businesses, where she undertook competitive intelligence analysis for the organization’s clients. She continued performing competitive intelligence analysis as an Analyst at CEIM (Centre d’entreprises et d’innovation de Montréal), an incubator of new technology companies. Just prior to joining IRICoR, she was Project Officer at Pharmabio Development, a Work Force sectoral Committee for pharmaceutical and biotechnology companies.

Ms. Molinier led her Engineering and Master II curricula in parallel. She holds a double Diploma in Project Management specializing in Biotechnology from Euromed Marseille – Management School and from ESIL (École Supérieure d’Ingénieurs de Luminy).

Audrey Segret joined IRICoR in 2015 as Project Manager, and her responsibilities include tasks such as recruiting innovative scientific projects for potential investment, and regularly following up and reporting the progress of portfolio projects according to their milestones. She has also developed key analytics tools for project management within the organization.

Dr. Segret brings over 8 years of experience in project management to IRICoR. Prior to joining IRICoR, she contributed to business development activities at Boralex by ensuring coordination with internal departments (development, regulatory affairs, financial and operations on sites), executive level and partners. Prior to joining Boralex, Audrey was a scientific consultant at Alma Consulting Group (France and Canada) where she was in charge of managing a portfolio of clients involved in a number of research and development activities. For each project, she identified ways to secure a claim process (SR&ED) and to review reports submitted to government institutions. Audrey provided scientific and financial support to more than 200 innovative business projects.

Dr. Segret holds a Ph.D. in Life Sciences (speciality: cardiovascular pharmacology) and her research project was realized in the UMR-CNRS 8162 Unit (Paris V – France) on the «Implication of the CXCL12 chimiokine and its CXCR4 and CXCR7 receptors in cardiac physiology and physiopathology».

0003_ASegret
Audrey Segret, Ph.D.Project manager

Audrey Segret joined IRICoR in 2015 as Project Manager, and her responsibilities include tasks such as recruiting innovative scientific projects for potential investment, and regularly following up and reporting the progress of portfolio projects according to their milestones. She has also developed key analytics tools for project management within the organization.

Dr. Segret brings over 8 years of experience in project management to IRICoR. Prior to joining IRICoR, she contributed to business development activities at Boralex by ensuring coordination with internal departments (development, regulatory affairs, financial and operations on sites), executive level and partners. Prior to joining Boralex, Audrey was a scientific consultant at Alma Consulting Group (France and Canada) where she was in charge of managing a portfolio of clients involved in a number of research and development activities. For each project, she identified ways to secure a claim process (SR&ED) and to review reports submitted to government institutions. Audrey provided scientific and financial support to more than 200 innovative business projects.

Dr. Segret holds a Ph.D. in Life Sciences (speciality: cardiovascular pharmacology) and her research project was realized in the UMR-CNRS 8162 Unit (Paris V – France) on the «Implication of the CXCL12 chimiokine and its CXCR4 and CXCR7 receptors in cardiac physiology and physiopathology».

Jean-Louis Brochu is a Pharmaceutical Intellectual Property expert with 10 years experience in providing International IP landscapes, freedom-to-operate, infringement and validity opinions on several pharmaceutical products.  He was the Lead Intellectual Property Scientist at Pharmascience, a leading Canadian generic pharmaceutical company.  Jean-Louis supported IP generation for the Innovative branch Pendopharm and provided IP support in all aspect of drug development; from idea generation, product development, submission, product launch to post-launch IP/litigation activities.

Prior to Pharmascience, Jean-Louis worked as a synthetic organic chemist for 5 years at the National Research Council Canada (NRCC), Painceptor Pharma and Sussex Research Laboratories in Ottawa.  Jean-Louis is a registered chemist with l’ordre des chimistes du Québec, has a B.Sc. in Biopharmaceutical Sciences – Medicinal Chemistry and an M.Sc. in Organic Chemistry, both at the University of Ottawa.  He was also a member of the Canadian Generic Pharmaceutical Association IP committee.

Jean-Louis Brochu, M.Sc.Senior Intellectual Property Manager

Jean-Louis Brochu is a Pharmaceutical Intellectual Property expert with 10 years experience in providing International IP landscapes, freedom-to-operate, infringement and validity opinions on several pharmaceutical products.  He was the Lead Intellectual Property Scientist at Pharmascience, a leading Canadian generic pharmaceutical company.  Jean-Louis supported IP generation for the Innovative branch Pendopharm and provided IP support in all aspect of drug development; from idea generation, product development, submission, product launch to post-launch IP/litigation activities.

Prior to Pharmascience, Jean-Louis worked as a synthetic organic chemist for 5 years at the National Research Council Canada (NRCC), Painceptor Pharma and Sussex Research Laboratories in Ottawa.  Jean-Louis is a registered chemist with l’ordre des chimistes du Québec, has a B.Sc. in Biopharmaceutical Sciences – Medicinal Chemistry and an M.Sc. in Organic Chemistry, both at the University of Ottawa.  He was also a member of the Canadian Generic Pharmaceutical Association IP committee.

Lizanne Boily joined IRICoR in 2015 as IRICoR’s administrative assistant. Prior to joining IRICoR, Lizanne worked at Versant Partners, a boutique investment bank specialized in biotechnology, which offered equity underwriting, private placement, and mergers and acquisitions advisory services. During that time, she contributed to the support in the administration of project management, accounting, human resources and compliance. She also worked as executive assistant to the Research Director at National Bank Financial and as a laboratory technician in chemistry at both universities and private companies. With more than 20 years of experience in the financial sector, Lizanne brings her knowledge in facilitating the coordination of different administrative tasks and responsibilities and ensures work efficiency among team members.

Lizanne holds a Bachelor degree in Sciences from Université de Montréal, a certification in Human Resources Management at HEC, and a Canadian Securities Course certification.

0007_LBoily
Lizanne BoilyClerical Technician

Lizanne Boily joined IRICoR in 2015 as IRICoR’s administrative assistant. Prior to joining IRICoR, Lizanne worked at Versant Partners, a boutique investment bank specialized in biotechnology, which offered equity underwriting, private placement, and mergers and acquisitions advisory services. During that time, she contributed to the support in the administration of project management, accounting, human resources and compliance. She also worked as executive assistant to the Research Director at National Bank Financial and as a laboratory technician in chemistry at both universities and private companies. With more than 20 years of experience in the financial sector, Lizanne brings her knowledge in facilitating the coordination of different administrative tasks and responsibilities and ensures work efficiency among team members.

Lizanne holds a Bachelor degree in Sciences from Université de Montréal, a certification in Human Resources Management at HEC, and a Canadian Securities Course certification.